Sars-COV-2 Vaccination DID Not Affect the Clinical Course of IGA Nephropathy in Latvian Adult Cohort

Kārlis Rācenis; Anna Jana Saulīte; Anna Popova; Mikus Saulīte; Juta Kroiča; Aivars Petersons; Harijs Cernevskis; Aivars Lejnieks; Kristīne Oļeiņika; Baiba Šlisere; Janis Seilis; Viktorija Kuzema

doi:10.1093/ndt/gfac067.012

Abstract

BACKGROUND AND AIMS: The current strategy to fight against the COVID-19 pandemic involves active patient vaccination. Patients with renal and autoimmune diseases are in high risk for severe COVID-19 infection [1]. Therefore they should be prioritized for vaccination. Immunoglobulin A nephropathy (IgAN) is one of the most common primary glomerulonephritis triggered by mucous membrane alteration; however, there is a discussion about vaccination-caused IgA flare [2]. The immunological nature of IgAN and misleading information in public sources leaves patients skeptical about whether to get vaccinated [3]. The study aimed to investigate the impact of SARS-CoV-2 vaccination on the clinical course of IgA nephropathy. METHOD: Adult patients treated in Pauls Stradins Clinical University Hospital with morphologically proven IgAN were included in the study. Patients with secondary IgAN were excluded. Evaluation of clinical and laboratory markers was performed on inclusion visit and on the second visit 6 months later. SARS-CoV-2 vaccination type and status were noted on both visits. Estimated GFR was calculated with CKD-EPI creatinine-cystatin equation. IBM SPSS Statistics version 27 and Microsoft Excel 10 were used for data analysis. RESULTS: The study involved 54 patients, 36 were unvaccinated and 18 were fully vaccinated. A significant difference between the two groups was observed by baseline proteinuria. Other differences were not observed. Fourteen patients were vaccinated with mRNA vaccine, 13 with Comirnaty and 1 with Spikevax, and four patients were vaccinated with Vaxzevria vector vaccine. The differences between the two groups are shown in Table 1. During study period, two patients had COVID-19 infection; a patient in the vaccinated group had COVID-19 prior to vaccination. CONCLUSION: SARS-CoV-2 vaccination did not affect the clinical course of IgA nephropathy. Our study results indicate that SARS-CoV-2 vaccination in IgA nephropathy patients was safe regarding renal function and disease activity markers. (Table Presented).

Original language	English
Article number	MO213
Pages (from-to)	i145-i146
Journal	Nephrology Dialysis Transplantation
Volume	37
Issue number	Supplement_3
DOIs	https://doi.org/10.1093/ndt/gfac067.012
Publication status	Published - 3 May 2022
Event	59th Congress of the European Renal Association (ERA): Innovation, Prevention, Preparedness - live in Paris & virtual, Paris, France Duration: 19 May 2022 → 22 May 2022 Conference number: 59 https://www.era-online.org/en/paris2022/ https://www.era-online.org/en/paris2022/wp-content/uploads/sites/6/2022/05/221686-ERA-59-Congress-Final-Programme_DEF_150dpi.pdf

Field of Science*

3.3 Health sciences
3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ndt/gfac067.012Licence: Other

SARS-COV-2 VACCINATION DID NOT AFFECT THE CLINICALFinal published version, 210 KB

https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfac067.012/6578473

Cite this

Rācenis, K., Jana Saulīte, A., Popova, A., Saulīte, M., Kroiča, J., Petersons, A., Cernevskis, H., Lejnieks, A., Oļeiņika, K., Šlisere, B., Seilis, J., & Kuzema, V. (2022). Sars-COV-2 Vaccination DID Not Affect the Clinical Course of IGA Nephropathy in Latvian Adult Cohort. Nephrology Dialysis Transplantation, 37(Supplement_3), i145-i146. Article MO213. https://doi.org/10.1093/ndt/gfac067.012

@article{d99b6bf1355247a8aa4edbaaa85b7282,

title = "Sars-COV-2 Vaccination DID Not Affect the Clinical Course of IGA Nephropathy in Latvian Adult Cohort",

abstract = "BACKGROUND AND AIMS: The current strategy to fight against the COVID-19 pandemic involves active patient vaccination. Patients with renal and autoimmune diseases are in high risk for severe COVID-19 infection [1]. Therefore they should be prioritized for vaccination. Immunoglobulin A nephropathy (IgAN) is one of the most common primary glomerulonephritis triggered by mucous membrane alteration; however, there is a discussion about vaccination-caused IgA flare [2]. The immunological nature of IgAN and misleading information in public sources leaves patients skeptical about whether to get vaccinated [3]. The study aimed to investigate the impact of SARS-CoV-2 vaccination on the clinical course of IgA nephropathy. METHOD: Adult patients treated in Pauls Stradins Clinical University Hospital with morphologically proven IgAN were included in the study. Patients with secondary IgAN were excluded. Evaluation of clinical and laboratory markers was performed on inclusion visit and on the second visit 6 months later. SARS-CoV-2 vaccination type and status were noted on both visits. Estimated GFR was calculated with CKD-EPI creatinine-cystatin equation. IBM SPSS Statistics version 27 and Microsoft Excel 10 were used for data analysis. RESULTS: The study involved 54 patients, 36 were unvaccinated and 18 were fully vaccinated. A significant difference between the two groups was observed by baseline proteinuria. Other differences were not observed. Fourteen patients were vaccinated with mRNA vaccine, 13 with Comirnaty and 1 with Spikevax, and four patients were vaccinated with Vaxzevria vector vaccine. The differences between the two groups are shown in Table 1. During study period, two patients had COVID-19 infection; a patient in the vaccinated group had COVID-19 prior to vaccination. CONCLUSION: SARS-CoV-2 vaccination did not affect the clinical course of IgA nephropathy. Our study results indicate that SARS-CoV-2 vaccination in IgA nephropathy patients was safe regarding renal function and disease activity markers. (Table Presented).",

author = "Kārlis Rācenis and {Jana Saulīte}, Anna and Anna Popova and Mikus Saulīte and Juta Kroi{\v c}a and Aivars Petersons and Harijs Cernevskis and Aivars Lejnieks and Kristīne Oļeiņika and Baiba {\v S}lisere and Janis Seilis and Viktorija Kuzema",

year = "2022",

month = may,

day = "3",

doi = "10.1093/ndt/gfac067.012",

language = "English",

volume = "37",

pages = "i145--i146",

journal = "Nephrology Dialysis Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "Supplement_3",

note = "59th Congress of the European Renal Association (ERA) : Innovation, Prevention, Preparedness, 59th ERA Congress ; Conference date: 19-05-2022 Through 22-05-2022",

url = "https://www.era-online.org/en/paris2022/, https://www.era-online.org/en/paris2022/wp-content/uploads/sites/6/2022/05/221686-ERA-59-Congress-Final-Programme_DEF_150dpi.pdf",

}

Rācenis, K, Jana Saulīte, A, Popova, A, Saulīte, M, Kroiča, J , Petersons, A , Cernevskis, H , Lejnieks, A , Oļeiņika, K , Šlisere, B, Seilis, J & Kuzema, V 2022, 'Sars-COV-2 Vaccination DID Not Affect the Clinical Course of IGA Nephropathy in Latvian Adult Cohort', Nephrology Dialysis Transplantation, vol. 37, no. Supplement_3, MO213, pp. i145-i146. https://doi.org/10.1093/ndt/gfac067.012

TY - JOUR

T1 - Sars-COV-2 Vaccination DID Not Affect the Clinical Course of IGA Nephropathy in Latvian Adult Cohort

AU - Rācenis, Kārlis

AU - Jana Saulīte, Anna

AU - Popova, Anna

AU - Saulīte, Mikus

AU - Kroiča, Juta

AU - Petersons, Aivars

AU - Cernevskis, Harijs

AU - Lejnieks, Aivars

AU - Oļeiņika, Kristīne

AU - Šlisere, Baiba

AU - Seilis, Janis

AU - Kuzema, Viktorija

N1 - Conference code: 59

PY - 2022/5/3

Y1 - 2022/5/3

N2 - BACKGROUND AND AIMS: The current strategy to fight against the COVID-19 pandemic involves active patient vaccination. Patients with renal and autoimmune diseases are in high risk for severe COVID-19 infection [1]. Therefore they should be prioritized for vaccination. Immunoglobulin A nephropathy (IgAN) is one of the most common primary glomerulonephritis triggered by mucous membrane alteration; however, there is a discussion about vaccination-caused IgA flare [2]. The immunological nature of IgAN and misleading information in public sources leaves patients skeptical about whether to get vaccinated [3]. The study aimed to investigate the impact of SARS-CoV-2 vaccination on the clinical course of IgA nephropathy. METHOD: Adult patients treated in Pauls Stradins Clinical University Hospital with morphologically proven IgAN were included in the study. Patients with secondary IgAN were excluded. Evaluation of clinical and laboratory markers was performed on inclusion visit and on the second visit 6 months later. SARS-CoV-2 vaccination type and status were noted on both visits. Estimated GFR was calculated with CKD-EPI creatinine-cystatin equation. IBM SPSS Statistics version 27 and Microsoft Excel 10 were used for data analysis. RESULTS: The study involved 54 patients, 36 were unvaccinated and 18 were fully vaccinated. A significant difference between the two groups was observed by baseline proteinuria. Other differences were not observed. Fourteen patients were vaccinated with mRNA vaccine, 13 with Comirnaty and 1 with Spikevax, and four patients were vaccinated with Vaxzevria vector vaccine. The differences between the two groups are shown in Table 1. During study period, two patients had COVID-19 infection; a patient in the vaccinated group had COVID-19 prior to vaccination. CONCLUSION: SARS-CoV-2 vaccination did not affect the clinical course of IgA nephropathy. Our study results indicate that SARS-CoV-2 vaccination in IgA nephropathy patients was safe regarding renal function and disease activity markers. (Table Presented).

AB - BACKGROUND AND AIMS: The current strategy to fight against the COVID-19 pandemic involves active patient vaccination. Patients with renal and autoimmune diseases are in high risk for severe COVID-19 infection [1]. Therefore they should be prioritized for vaccination. Immunoglobulin A nephropathy (IgAN) is one of the most common primary glomerulonephritis triggered by mucous membrane alteration; however, there is a discussion about vaccination-caused IgA flare [2]. The immunological nature of IgAN and misleading information in public sources leaves patients skeptical about whether to get vaccinated [3]. The study aimed to investigate the impact of SARS-CoV-2 vaccination on the clinical course of IgA nephropathy. METHOD: Adult patients treated in Pauls Stradins Clinical University Hospital with morphologically proven IgAN were included in the study. Patients with secondary IgAN were excluded. Evaluation of clinical and laboratory markers was performed on inclusion visit and on the second visit 6 months later. SARS-CoV-2 vaccination type and status were noted on both visits. Estimated GFR was calculated with CKD-EPI creatinine-cystatin equation. IBM SPSS Statistics version 27 and Microsoft Excel 10 were used for data analysis. RESULTS: The study involved 54 patients, 36 were unvaccinated and 18 were fully vaccinated. A significant difference between the two groups was observed by baseline proteinuria. Other differences were not observed. Fourteen patients were vaccinated with mRNA vaccine, 13 with Comirnaty and 1 with Spikevax, and four patients were vaccinated with Vaxzevria vector vaccine. The differences between the two groups are shown in Table 1. During study period, two patients had COVID-19 infection; a patient in the vaccinated group had COVID-19 prior to vaccination. CONCLUSION: SARS-CoV-2 vaccination did not affect the clinical course of IgA nephropathy. Our study results indicate that SARS-CoV-2 vaccination in IgA nephropathy patients was safe regarding renal function and disease activity markers. (Table Presented).

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000813350700213

U2 - 10.1093/ndt/gfac067.012

DO - 10.1093/ndt/gfac067.012

M3 - Meeting Abstract

SN - 0931-0509

VL - 37

SP - i145-i146

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

IS - Supplement_3

M1 - MO213

T2 - 59th Congress of the European Renal Association (ERA)

Y2 - 19 May 2022 through 22 May 2022

ER -